Skip to content

Study on prevention mild to moderate Alzheimer's disease from exacerbating through invigorating spleen and kidney

Study on prevention mild to moderate Alzheimer's disease from exacerbating through invigorating spleen and kidney

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006842
Enrollment
Unknown
Registered
2022-12-01
Start date
2022-12-01
Completion date
Unknown
Last updated
2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

Treatment group:Traditional Chinese medicine combined with donepezil

Sponsors

Longhua Hospital Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.The diagnostic criteria of Western medicine and traditional Chinese medicine for Alzheimer's disease was met; 2.TCM syndrome differentiation belongs to the spleen and kidney deficiency type; 3.Clinical dementia rating,Montreal Cognitive Assessment,Mini-mental State Examination scale was used to screen patients with mild to moderate Alzheimer's disease (referring to CDR scale score of CDR score 1 or 2 patients 10 points =MMSE score < 27 points); 4.Both men and women aged 50-85 years old are acceptable; 5.Informed consent was obtained from patients or their family members to voluntarily participate in this study.

Exclusion criteria

Exclusion criteria: 1.The diagnostic and inclusion criteria were not met; 2.Patients with severe neurological deficits such as hemiplegia, aphasia, and visual and hearing impairment; 3.Patients with cognitive impairment caused by other system diseases such as severe circulatory system, digestive system, urinary system, endocrine system and other diseases; 4.Patients with underlying diseases affecting the oral absorption and metabolism of drugs; 5.Patients with adverse addictions such as alcohol and drug abuse, psychotropic drug abuse and antidepressant drug abuse affected cognitive assessment; 6.Patients with serious life-threatening primary diseases and mental disorders; 7.People with allergic constitution; 8.Taking other cognitive-improving Chinese medicine or Chinese patent medicine; 9.Patients enrolled in other clinical trials within the past 3 months.

Design outcomes

Primary

MeasureTime frame
Chinese Medicine Symptom Score Scale;Montreal Cognitive Assessment;Mini-mental State Examination;Alzheimer's Disease Assessment Scale-Cognitive section;

Secondary

MeasureTime frame
Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale;Clinical Dementia Rating;Neuropsychiatric Inventory;

Countries

China

Contacts

Public ContactZhengyu Lu

Longhua Hospital Shanghai University of Traditional Chinese Medicine

lu_zhengyu@163.com+86 18917763596

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026